| Dr Ross Bauer, MD | |
|
2 Medical Park Dr, Suite 10, West Nyack, NY 10994-1965 | |
| (845) 354-5000 | |
| (845) 354-9469 |
| Full Name | Dr Ross Bauer |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 19 Years |
| Location | 2 Medical Park Dr, West Nyack, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336308873 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 256090 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Hospital Of Suffern | Suffern, NY | Hospital |
| St Anthony Community Hospital | Warwick, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bon Secours Charity Health System Medical Group, P.c. | 1658262084 | 147 |
News Archive
A major national effort to expand the reach of cancer immunotherapy to benefit more patients will draw upon the expertise of a team of researchers at The University of Texas MD Anderson Cancer Center.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the Cancer and Metabolism: Pathways to the Future meeting in Edinburgh, Scotland, as well as two additional posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics" November 16-19, 2010, in Berlin, Germany.
The use of complementary and alternative medicine (CAM) is increasing for the treatment of menopausal symptoms but often without the guidance of a clinician. That's according to a new study reported online today in Menopause, the journal of the North American Menopause Society.
Skin from a factory - this has long been the dream of pharmacologists, chemists and doctors. Research has an urgent need for large quantities of 'skin models', which can be used to determine if products such as creams and soaps, cleaning agents, medicines and adhesive bandages are compatible with skin, or if they instead will lead to irritation or allergic reactions for the consumer. Such test results are seen as more meaningful than those from animal experiments, and can even make such experiments largely superfluous.
Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.
› Verified 7 days ago
| Entity Name | Hudson Valley Radiology Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174574115 PECOS PAC ID: 4486567690 Enrollment ID: O20040128000958 |
News Archive
A major national effort to expand the reach of cancer immunotherapy to benefit more patients will draw upon the expertise of a team of researchers at The University of Texas MD Anderson Cancer Center.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the Cancer and Metabolism: Pathways to the Future meeting in Edinburgh, Scotland, as well as two additional posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics" November 16-19, 2010, in Berlin, Germany.
The use of complementary and alternative medicine (CAM) is increasing for the treatment of menopausal symptoms but often without the guidance of a clinician. That's according to a new study reported online today in Menopause, the journal of the North American Menopause Society.
Skin from a factory - this has long been the dream of pharmacologists, chemists and doctors. Research has an urgent need for large quantities of 'skin models', which can be used to determine if products such as creams and soaps, cleaning agents, medicines and adhesive bandages are compatible with skin, or if they instead will lead to irritation or allergic reactions for the consumer. Such test results are seen as more meaningful than those from animal experiments, and can even make such experiments largely superfluous.
Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.
› Verified 7 days ago
| Entity Name | Bon Secours Charity Health System Medical Group, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487694345 PECOS PAC ID: 1658262084 Enrollment ID: O20040323001971 |
News Archive
A major national effort to expand the reach of cancer immunotherapy to benefit more patients will draw upon the expertise of a team of researchers at The University of Texas MD Anderson Cancer Center.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the Cancer and Metabolism: Pathways to the Future meeting in Edinburgh, Scotland, as well as two additional posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics" November 16-19, 2010, in Berlin, Germany.
The use of complementary and alternative medicine (CAM) is increasing for the treatment of menopausal symptoms but often without the guidance of a clinician. That's according to a new study reported online today in Menopause, the journal of the North American Menopause Society.
Skin from a factory - this has long been the dream of pharmacologists, chemists and doctors. Research has an urgent need for large quantities of 'skin models', which can be used to determine if products such as creams and soaps, cleaning agents, medicines and adhesive bandages are compatible with skin, or if they instead will lead to irritation or allergic reactions for the consumer. Such test results are seen as more meaningful than those from animal experiments, and can even make such experiments largely superfluous.
Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.
› Verified 7 days ago
| Entity Name | Lenox Hill Radiology & Medical Imaging Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821036807 PECOS PAC ID: 2264424712 Enrollment ID: O20040402000403 |
News Archive
A major national effort to expand the reach of cancer immunotherapy to benefit more patients will draw upon the expertise of a team of researchers at The University of Texas MD Anderson Cancer Center.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the Cancer and Metabolism: Pathways to the Future meeting in Edinburgh, Scotland, as well as two additional posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics" November 16-19, 2010, in Berlin, Germany.
The use of complementary and alternative medicine (CAM) is increasing for the treatment of menopausal symptoms but often without the guidance of a clinician. That's according to a new study reported online today in Menopause, the journal of the North American Menopause Society.
Skin from a factory - this has long been the dream of pharmacologists, chemists and doctors. Research has an urgent need for large quantities of 'skin models', which can be used to determine if products such as creams and soaps, cleaning agents, medicines and adhesive bandages are compatible with skin, or if they instead will lead to irritation or allergic reactions for the consumer. Such test results are seen as more meaningful than those from animal experiments, and can even make such experiments largely superfluous.
Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ross Bauer, MD 532 Broadhollow Rd, Suite 142, Melville, NY 11747-3672 Ph: (516) 931-0041 | Dr Ross Bauer, MD 2 Medical Park Dr, Suite 10, West Nyack, NY 10994-1965 Ph: (845) 354-5000 |
News Archive
A major national effort to expand the reach of cancer immunotherapy to benefit more patients will draw upon the expertise of a team of researchers at The University of Texas MD Anderson Cancer Center.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the Cancer and Metabolism: Pathways to the Future meeting in Edinburgh, Scotland, as well as two additional posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics" November 16-19, 2010, in Berlin, Germany.
The use of complementary and alternative medicine (CAM) is increasing for the treatment of menopausal symptoms but often without the guidance of a clinician. That's according to a new study reported online today in Menopause, the journal of the North American Menopause Society.
Skin from a factory - this has long been the dream of pharmacologists, chemists and doctors. Research has an urgent need for large quantities of 'skin models', which can be used to determine if products such as creams and soaps, cleaning agents, medicines and adhesive bandages are compatible with skin, or if they instead will lead to irritation or allergic reactions for the consumer. Such test results are seen as more meaningful than those from animal experiments, and can even make such experiments largely superfluous.
Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.
› Verified 7 days ago
Mr. Alexander M. Schwartz, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2 Centerock Rd, West Nyack, NY 10994 Phone: 845-703-6999 Fax: 845-703-6297 | |
Dr. Marissa Christina Theofanides, MD Urology Medicare: May Accept Medicare Assignments Practice Location: 2 Centerock Rd, West Nyack, NY 10994 Phone: 845-703-6999 Fax: 845-703-6297 | |
Mitchell Fraiman, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2 Medical Park Dr, West Nyack, NY 10994 Phone: 845-354-5000 Fax: 845-354-9469 | |
Kathleen Latino, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 2 Medical Park Dr, West Nyack, NY 10994 Phone: 854-354-5000 Fax: 845-354-9469 | |
Richard Evans, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2 Medical Park Dr, West Nyack, NY 10994 Phone: 845-354-5000 Fax: 845-354-9469 | |
Richard Kroll, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2 Medical Park Dr, West Nyack, NY 10994 Phone: 845-354-5000 Fax: 854-354-9469 |